Topical Dimethylcurcumin Composition for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions for topical application of curcuminoids face challenges in maintaining therapeutically effective and stable amounts of the API, often experiencing issues with solubility, stability, and phase separation, which affect their efficacy and shelf life.
Innovation Solution
A pharmaceutical composition comprising a curcuminoid compound (dimethylcurcumin) in a range of 0.001% to 0.2% w/w and an oil solvent system of at least 8% w/w, along with specific surfactants, esters, and other components, is formulated to ensure even distribution and stability, preventing crystal formation and impurity formation, thereby maintaining solubility and stability for up to 5 years.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcuminoid compounds are formulated in conventional pharmaceutical compositions, then therapeutic efficacy is achieved, but solubility and stability problems occur leading to phase separation
Solution Approach 1:
The patent introduces an intermediary oil-soluble carrier compound that mediates between the hydrophobic curcuminoid API and the aqueous formulation environment. This carrier compound facilitates solubility and prevents phase separation by acting as a bridge between lipid-soluble and water-soluble components, resolving the contradiction between maintaining therapeutic stability and preventing phase separation.
Solution Approach 2:
The patent modifies formulation parameters by specifying precise concentration ranges (0.001-0.2% w/w for API, at least 8% w/w for oil solvent system) and controlling pH levels. These parameter changes optimize the balance between solubility, stability, and prevention of phase separation, allowing the formulation to maintain both therapeutic efficacy and compositional stability.
2Reliability
If curcuminoid compounds are formulated at therapeutically effective concentrations, then efficacy is maintained, but crystal formation occurs reducing stability
Solution Approach 1:
The oil-soluble carrier compound acts as a mediator that prevents direct crystallization of the curcuminoid API at therapeutically effective concentrations. By incorporating the API into this intermediary carrier matrix, the formulation maintains therapeutic efficacy while preventing crystal formation that would compromise stability.
Solution Approach 2:
The patent controls concentration parameters within specific ranges (0.001-0.2% w/w for API) and adjusts the oil solvent system composition to prevent supersaturation and crystal formation. These parameter optimizations allow maintenance of therapeutic efficacy without triggering crystallization.
3Ease of manufacture
If conventional formulation methods are used, then manufacturing is simpler, but impurity formation increases affecting shelf life
Solution Approach 1:
The patent specifies precise parameter ranges including pH control, API concentration (0.001-0.2% w/w), and oil solvent system content (at least 8% w/w). These controlled parameter changes prevent degradation reactions and impurity formation during manufacturing and storage, extending shelf life while maintaining formulation feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides stable and therapeutically effective delivery of dimethylcurcumin, maintaining solubility and preventing impurity formation, ensuring long-term stability and efficacy in topical applications.
Implementation Method 1
maintaining solubility and preventing impurity formation
Data Source
AI summary
Provided is a pharmaceutical composition that may be suitable for topical application. The pharmaceutical composition for topical application includes dimethylcurcumin and/or a salt thereof as an active pharmaceutical ingredient in a range of from 0.001% w/w to 0.2% w/w. The pharmaceutical composition for topical application may further include an oil solvent system in an amount of at least 8% w/w.